Glutathione S-transferase gene polymorphisms (GSTT1 and GSTM1) and risk of schizophrenia: A case–control study in Chinese Han population

Xin Zhang, MMa, Jinmei Yang, MBb, Xia Liu, MMA, Gaofeng Zhao, MMA, Xue Li1, Guanglei Xun, MDC,∗

Abstract
Schizophrenia (SCZ) is a chronic disability disorder related to oxidative stress. Glutathione S-transferase (GST) is a group enzyme that protects cells and tissues from oxidative stress damage. Among GSTs, GSTT1 and GSTM1 have well defined genetic polymorphisms. The purpose of our research was to explore the correlation between GSTT1 and GSTM1 polymorphism and SCZ risk in Chinese Han population.

A total of 650 subjects (386 SCZ patients and 264 healthy individuals) were included in this case–control designed study. The GSTT1 and GSTM1 polymorphisms were analyzed by multiplex polymerase chain reaction (PCR). We explored the relationship between these 2 polymorphisms and the risk of SCZ.

We found that the GSTT1 null genotype had a protective effect on the development of SCZ [odds ratio (OR) = 0.601, 95% confidence interval (95% CI) = 0.412–0.896, P = 0.031]. We also found that the combination of null genotypes of the GSTT1 and GSTM1 genes was made at a lower risk of SCZ [OR = 0.452, 95% CI = 0.238–0.845, P = 0.028]. However, we found no correction between Positive and Negative Syndrome Scale score (PANSS) and GSTM1, GSTT1 genotypes in SCZ patients.

Our finding revealed that GSTT1 null polymorphisms may be related to the reduced risk of SCZ in Chinese Han population, and this risk was further reduced with the combination of GSTT1 null polymorphisms and GSTM1 null polymorphisms.

Abbreviations: BD = bipolar disorder, DEPC = diethyl pyrocarbonate, DSM = diagnostic and Statistical Manual of mental disorders, EDTA = ethylenediamine tetraacetic acid, GSTs = Glutathione S-transferase, MDD = major depression disorder, PANSS = Positive and Negative Syndrome Scale, PCR = polymerase chain reaction, SCZ = Schizophrenia.

Keywords: gene polymorphisms, glutathione S-transferases, oxidative stress, schizophrenia

1. Introduction
Schizophrenia (SCZ) is a chronic disability disorder with a lifetime prevalence estimate of 4 per 1000 individuals in developing countries.1 SCZ is a complex polygenetic disorder with over 80% heritability.2 To date, the underlying genetic and molecular mechanisms for SCZ are still not fully understood.

Increasing evidences support that the pathophysiology of SCZ involves oxidative stress.3,4 Oxidative stress is general related to many disease, including vascular disease,5 cancer,6 neurodegenerative diseases,7 and psychosis.8 Oxidative stress refers to an increase in reactive oxygen species or a decrease in antioxidant capacity in cells.9 Granulocyte colony-stimulating factor (G-CSF) is a growth factor that stimulates the proliferation, differentiation, and survival of myeloid hematopoietic cells.10 More and more evidences show that G-CSF is easy to combine with its receptor through blood–brain barrier, and play a role in mobilizing hematopoietic stem cells and bone marrow mesenchymal stem cells, anti-apoptotic, anti-inflammatory, promoting neuron differentiation and angiogenesis.10,11 Abnormal oxidative stress parameters in patients with SCZ have been found in blood,12 platelets,13 cerebrospinal fluid,14 and red blood cells.15

Glutathione S-transferases (GSTs) are classified as α, μ, θ, p, Ω, and θ, and they are encoded by GSTA, GSTM, GSTO, GSTP, GSTT, and GSTZ genes, respectively.16 GSTs are phase II biotransferase, involved in detoxification of various toxicants.17 GSTT1 (OMIM: 600436) and GSTM1 (OMIM: 138350) have
definite genetic polymorphisms.[18–21] There are studies showing that the frequencies of GSTT1 and GSTM1 gene variants are different among ethnic groups.[22,23] The genotype distributions of GSTT1 genes as well as GSTM1 genes variants in Chinese populations are similar to those of Korean populations,[24,25] but were different from the Europeans, American, and Africans.[26,27] GSTT1 null genotype and GSTM1 null genotype could lead to complete absence of the enzyme,[28] further increasing the risks of various diseases, such as diabetes,[29] male infertility,[30] hypertension,[31] and some types of cancer.[32–34] To date, many researches have indicated the correlation between SCZ and gene polymorphisms of GSTT1, GSTM1,[35–38] However, the results were inconsistent. We found that there were few studies where the relationship between GSTT1, GSTM1 gene polymorphisms, and SCZ among Chinese people was investigated. Therefore, a case-control designed study, including 386 SCZ patients and 264 healthy individuals, was conducted to explore the relationship between susceptibility to SCZ among Chinese Han population and GSTT1 and GSTM1 polymorphism.

2. Materials and methods

2.1. Subjects

A total of 386 patients with SCZ (SCZ group) and 264 healthy individuals (control group) were included in our study. All subjects were between 18 and 80 years old. The demographic characteristics of the subjects are summarized in Table 1. Three hundred eighty-six SCZ patients were recruited from Shandong Mental Health Center. Diagnosis were assessed by at least 2 psychiatrists according to the Diagnostic and Statistical Manual of mental disorders (DSM)-5 criteria.[39] Moreover, Positive and Negative Syndrome Scale (PANSS) was used to assess the severity of SCZ.[40] These 386 SCZ patients had no other mental disorder, including bipolar disorder (BD), major depression disorder (MDD), substance abuse, or mental retardation. The study was approved by the Ethics committee of Shandong Mental Health Center. Informed consent were obtained from all subjects. The control individuals were recruited in the same geographic area. They had no history of mental disorder including SCZ, MD, BD, substance abuse. Moreover, those who had a first-degree relative with SCZ were excluded. Their current psychological status and medical history were evaluated through unstructured interview.

2.2. Genotyping of GSTT1 and GSTM1 polymorphisms

For genotyping, 5 mL cubital venous blood was drawn into an ethylenediamine tetraacetic acid (EDTA) tube. Gnomic DNA was isolated from whole blood by DNA extraction kit (Jianlun Biotechnology Co., Ltd, Guangzhou, China; No. JL45852). DNA purity was determined by Epoch microplate spectrophotometer (Bio Tek). In this study, we used multiplex PCR assay to assess the null or presence of GSTT1 and GSTM1 gene null polymorphism. The \( \beta \)-globin gene was used as an internal reference. The amplification reaction was conducted at the final volume of 20 \( \mu \)L, containing 7 \( \mu \)L diethyl pyrocarbonate (DEPC) water, 1 \( \mu \)L DNA, 1 \( \mu \)L primer (10 \( \mu \)mol/L), and 10 \( \mu \)L Taq polymerase master mix (Hengfei Biotechnology Co., Ltd, Shanghai, China; No. PCR-TAQ-MX-1). PCR was done using Veriti Dx Thermal Cycler (ABI). The amplification condition in our study was as follows: introductory denaturation for 300 seconds at 94°C, amplification for 30 cycles, denaturation for 60 seconds at 92°C, annealing at 60°C for 0.5 minutes, and final extension at 72°C for 300 seconds. Electrophoretic amplification of PCR products was performed on 2% agarose gel (Huaizhong Haiwei Gene Technology Co., Ltd, Beijing, China; No. S2016) and stained with ethidium bromide (Zhijie Fangyuan Technology Co., Ltd, Beijing, China; No. Amresco 0492). In this study, we took the gel imagings under UV transilluminator (Cleaver, UK). The primer sequences and the sizes of PCR products are summarized in Table 2 and Fig. 1, respectively.

2.3. Statistical analysis

SPSS 19.0 was used for statistical analyses. Comparison between SCZ group and controls group were performed using Student t
test and \( \chi^2 \) test. In order to evaluate the combined effects of GSTT1 and GSTM1, we used logistic regression analysis. All tests in this study were 2-tailed. \( P < .05 \) was statistically significant.

3. Results

A total of 650 subjects were included in present research. Three hundred eighty-six were patients with SCZ who aged 41.02 ± 5.01 years, and 264 were healthy individuals aged 41.02 ± 5.01 years. There was no statistical difference in demographic data between SCZ patients and healthy individuals (\( P > .05 \)).

In our study, Hardy–Weinberg test was not performed to GSTT1 and GSTM1 genotypes, due to that multiplex PCR assay could not distinguish the heterozygous presence of the allele (null/ presence) from the homozygous presence. Nevertheless, the distributions of GSTT1-null and GSTM1-null polymorphism in our study were not different from the previous studies in Chinese Han population.\(^{41-43}\)

Genotype frequencies of SCZ patients and healthy individuals are summarized in Table 3. The frequencies of GSTM1 null genotype were 53.89% and 56.82% for SCZ patients and healthy individuals, respectively. The frequencies of GSTT1 null genotype were 45.60% and 50.38% for SCZ patients and healthy individuals, respectively. The GSTT1 null polymorphism showed a reduced risk of SCZ (\( P = .031 \)). However, the GSTM1 null genotype tended to reduce the risk of SCZ, but there was no significant difference (\( P = .197 \)). Furthermore, we found that 24.09% of SCZ patients and 29.55% of healthy individuals carried both null genotypes of GSTT1 and GSTM1 genes, which reduced the risk of SCZ (\( P = .028 \)).

We found no association between PANSS score and GSTM1, GSTT1 genotypes in SCZ patients (Table 4).

4. Discussion

SCZ is a complex polygenic disorder. Increasing evidences support that the pathophysiology of SCZ involves oxidative stress.\(^{3,4}\) The relationship between GST gene polymorphism and SCZ susceptibility had been studied in many previous studies, but the results were inconclusive. GSTT1 (OMIM: 600436) and GSTM1 (OMIM: 138350) have definite genetic polymorphisms.\(^{18-21}\) In our research, we evaluated the relationship between SCZ susceptibility and polymorphism of GSTT1 and GSTM1. Our research is first to explore the relationship between these 2 genetic polymorphisms and SCZ in Chinese Han population. We found that GSTT1 null polymorphism may be related to reduce the risk of SCZ in Chinese people. Furthermore, when GSTT1 null polymorphisms and GSTM1 null polymorphisms are combined, the risk of SCZ was decreased.

Our results indicated that GSTT1 active genotype was associated with SCZ. Previous study has shown that GSTT1 gene maps on region 2qq11.2, and this gene is associated with susceptibility to SCZ by genome scanning analysis.\(^{44}\) Moreover, several reports showed that GSTT1 gene increased the risk of certain types of cancer.\(^{32-34,45}\) However, there is not a common rule, the disease protection effect of GSTT1 null genotype has also been found.\(^{29,46}\) GSTT1 is associated with the metabolism of detoxification. In mammals, the empty genotype encoding GSTT1 protein leads to a lack of active protein,\(^{47}\) reduces the detoxification ability of specific substrate induced by oxidative stress damage, and increases sensitivity to oxidative DNA damage.\(^{48}\) Previous studies have also found that SCZ patients had a higher proportion of GSTT1 enzymes than healthy individuals.\(^{44}\) The fact that GSTT1 active genotype is a risk factor for SCZ has been confirmed in many previous studies.\(^{35,37,49}\) In this study, the null genotype proportion of GSTT1 were 45.60% and 50.38% for SCZ patients and healthy individuals, respectively. The results indicated that GSTT1 could be a candidate gene for predisposing to SCZ in Chinese Han population. The results of our study are supported by Raffa et al.\(^{17}\) and they suggested that GSTT1 null genotype might decrease the risk of SCZ in Tunisian. However, Pejovic-Milovancevic et al.\(^{19}\) and Matsuzawa et al.\(^{50}\) have demonstrated that GSTT1 polymorphism is not associated with susceptibility to SCZ independently.

GSTM1 gene has also been emphasized in genetic epidemiologic studies in SCZ patients. GSTM1 null genotype is the result of a 1500 base pairs deletion. Previous study indicated that GSTM1 null genotype resulted in a complete lack of GSTM1 activity.\(^{51}\) Thus, GSTM1 null genotype could lead to the decrease of oxidative stress. Present study showed that GSTM1 null genotype in SCZ patients and healthy individuals was 53.89% and 56.82%, respectively, although there was no
Association with gene polymorphism. We did not examine whether treatment response and prognosis are associated with gene polymorphism. Besides, we did not examine whether treatment response and prognosis are associated with gene polymorphism. In the future, we should study the relationship between SCZ severity and GSTM1 polymorphisms as well as GSTT1 polymorphisms. The relationship between these 2 gene polymorphisms and drug response and disease prognosis needs to be further explored in the future.

**Author contributions**

Table 3

| Genotype          | SCZ patients (n, %) | Controls (n, %) | OR     | 95% CI         | P   |
|-------------------|---------------------|----------------|--------|----------------|-----|
| GSTT1             |                     |                |        |                |     |
| Present (+)       | 210 (54.60)         | 131 (49.62)    | 1 (ref) | 0.412–0.986    | .031|
| Null (−)          | 176 (45.60)         | 133 (50.38)    | 0.601  |                |     |
| GSTM1             |                     |                |        |                |     |
| Present (+)       | 178 (46.11)         | 114 (43.18)    | 1 (ref) | 0.513–1.167    | .197|
| Null (−)          | 208 (53.89)         | 150 (56.82)    | 0.781  |                |     |
| GSTT1/GSTM1       |                     |                |        |                |     |
| (+/−)             | 95 (24.61)          | 59 (22.35)     | 1 (ref) |                |     |
| (−/−)             | 93 (24.69)          | 76 (29.59)     | 0.452  | 0.238–0.845    | .028|
| (+/+−)            | 115 (29.79)         | 72 (27.27)     | 0.742  | 0.421–1.322    | .310|
| (−/+−)            | 83 (21.50)          | 55 (20.83)     | 0.653  | 0.384–1.296    | .158|

95% CI = 95% confidence interval. GST = glutathione S-transferases, OR = odds ratio, SCZ = schizophrenia.

Table 4

| PANSS scale                                      | Present (+) | Null (+) | t      | P    |
|-------------------------------------------------|-------------|----------|--------|------|
| GSTT1                                           | n = 210     | n = 176  |        |      |
| PANSS-positive symptom score                     | 26.10 ± 5.36| 26.35 ± 4.05| 0.521  | .603 |
| PANSS-negative symptom score                     | 30.26 ± 5.52| 30.99 ± 7.67| 1.789  | .075 |
| PANSS general psychopathology symptom score      | 54.36 ± 6.36| 53.83 ± 13.23| 0.653  | .527 |
| PANSS total score                                | 108.36 ± 15.36| 109.21 ± 16.35| 0.523  | .601 |
| GSTM1                                           | n = 178     | n = 208  |        |      |
| PANSS-positive symptom score                     | 27.69 ± 5.29| 26.31 ± 8.96| 1.872  | .062 |
| PANSS-negative symptom score                     | 30.59 ± 8.02| 29.67 ± 7.98| 1.126  | .261 |
| PANSS general psychopathology symptom score      | 54.39 ± 8.35| 53.04 ± 7.27| 1.679  | .094 |
| PANSS total score                                | 108.39 ± 17.95| 109.37 ± 20.22| 0.010  | .992 |

GST = glutathione S-transferases, PANSS = Positive and Negative Syndrome Scale.

SCZ is a complex polygenetic disorder. Here, we demonstrated that GSTT1 null polymorphisms may be related to decrease the risk of SCZ in Chinese Han population, and that the risk was further reducing with the combination of both GSTT1 null polymorphisms and GSTM1 null polymorphisms. The relationship between these 2 gene polymorphisms and drug response and disease prognosis needs to be further explored in the future.

**References**

[1] Esan OB, Ojagbemi A, Gureje O. Epidemiology of schizophrenia: an update with a focus on developing countries. Int Rev Psychiatry 2012;24:387–92.
[2] Foley C, Corvin A, Nakagome S. Genetics of schizophrenia: ready to translate? Curr Psychiatry Rep 2017;19:61.
[3] Solberg DK, Refsum H, Andreassen OA. A five-year follow-up study of antioxidants, oxidative stress and polyunsaturated fatty acids in schizophrenia. Acta Neuropsychiatr 2019;31:202–12.
[4] Upthegrove R, Khandaker GM. Cytokines, oxidative stress and cardiovascular markers of inflammation in schizophrenia. Curr Top Behav Neurosci 2019;44:49–66.
[5] Kim YW, Byyova TV. Oxidative stress in angiogenesis and vascular disease. Blood 2014;123:625–31.
[6] Chikara S, Nagaprasanthna LD, Singh J, et al. Oxidative stress and dietary phytochemicals: role in cancer chemoprevention and treatment. Cancer Lett 2018;413:122–34.
[7] Chen ZH, Xian JF, Luo LP. Association between GSTM1, GSTT1, and GSTP1 polymorphisms and gastric cancer risk, and their interactions with environmental factors. Genet Mol Res 2017;16:
Dietrich-Muszalska A, Olas B, Rabe-Jablonska J. Oxidative stress in psychosis and psychosis risk. Int J Mol Sci 2017;18:651.

Dwivedi P, Greis KD. Granulocyte colony stimulating factor receptor (G-CSFR) signaling in severe congenital neutropenia, chronic neutrophilic leukemia and related malignancies. Exp Hematol 2016;9:2.

Bai ZL, Li XS, Chen GY, et al. Serum oxidative stress marker levels in unmedicated and medicated patients with schizophrenia. J Mol Neurosci 2018;66:426–36.

Dietrich-Muszalska A, Olas B, Rabe-Jablonska J. Oxidative stress in psychosis and psychosis risk. Int J Mol Sci 2017;18:651.

Dwivedi P, Greis KD. Granulocyte colony stimulating factor receptor (G-CSFR) signaling in severe congenital neutropenia, chronic neutrophilic leukemia and related malignancies. Exp Hematol 2016;9:2.

Bai ZL, Li XS, Chen GY, et al. Serum oxidative stress marker levels in unmedicated and medicated patients with schizophrenia. J Mol Neurosci 2018;66:426–36. 

Yu C, Hequn C, Longfei L, et al. GSTM1 and GSTT1 polymorphisms are associated with increased bladder cancer risk: evidence from updated meta-analysis. Oncotarget 2017;8:3246–53.

Saitou M, Ishida T. Distributions of the GSTM1 and GSTT1 null genotypes in a Tunisian population. Gene 2013;512:282–5.

Saruwatari J, Yasui-Furukori N, Kamibashi R, et al. Possible associations between antioxidant enzyme polymorphisms and metabolic abnormalities in patients with schizophrenia. Neuropsychiatr Dis Treat 2013;9:1683–98.

Tandon R, Gaebel W, Barc DM, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res 2013;150:3–10.

Wolthus Je, Dimgemas PM, Schene AH, et al. Component structure of the positive and negative syndrome scale (PANSS) in patients with recent-onset schizophrenia and spectrum disorders. Psychopharmacology (Berl) 2000;150:399–403.

Liu K, Lin X, Zhou Q, et al. The associations between two vital GSTs genetic polymorphisms and lung cancer risk in the Chinese population: evidence from 71 studies. PLoS One 2014;9:e10372.

Qi R, Gu Z, Zhou L. The effect of GSTT1, GSTM1 and GSTP1 gene polymorphisms on the susceptibility of age-related cataract in Chinese Han population. Int J Clin Exp Med 2015;8:19448–53.

Wang X, Li W, Liu W, et al. GSTM1 and GSTT1 gene polymorphisms as major risk factors for bronchopulmonary dysplasia in a Chinese Han population. Gene 2014;533:48–51.

Saadat M, Mobayed F, Farrashbandi H. Genetic polymorphism of glutathione S-transferase T1: a candidate genetic modifier of individual susceptibility to schizophrenia. Psychiatry Res 2007;153:87–91.

Rebeck TR. Molecular epidemiology of the human glutathione S-transferase gene polymorphisms GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6:733–43.

Guan L, Fan P, Liu X, et al. Association study between GSTT1 and GSTM1 polymorphisms and risk of preeclampsia in Chinese population. Eur J Obstet Gynecol Reprod Biol 2016;204:31–5.

Pembile S, Schroeder KR, Spencer SR, et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a general polymorphism. Biochemical Journal 1994;300:271–6.

Song Y, Shan Z, Luo C, et al. Glutathione S-transferase T1 (GSTT1) null polymorphism, smoking, and their interaction in coronary heart disease: a comprehensive meta-analysis. Heart Lung Circ 2017;26:362–70.

Kim SK, Kang SW, Chung JH, et al. Genetic polymorphisms of glutathione-related enzymes (GSTM1, GSTT1, and GSTP1) and schizophrenia risk: a meta-analysis. Int J Mol Sci 2015;16:19602–11.

Matsuzawa D, Hashimoto K, Hashimoto T, et al. Association study in Brazilian patients. PLoS One 2017;12:e0183812.

Raffa M, Lakhdir R, Ghachem M, et al. Relationship between GSTM1 and GSTT1 polymorphisms and schizophrenia: a case-control study in a Tunisian population. Gene 2013;512:282–5.

Pacakti S, Polimanti R, Porreca F, et al. GSTT1 and GSTM1 gene polymorphisms in European and African populations. Mol Biol Rep 2011;38:1225–30.

Sattawat VW, Zhang ZF, Yu GP, et al. GSTM1 and GSTT1 null genotypes and the risk of gastric cancer: a case-control study in a Chinese population. Cancer Epidemiol Biomarkers Prev 2009;18:73–80.

Pacakti S, Polimanti R, Porreca F, et al. GSTT1 and GSTM1 gene polymorphisms in European and African populations. Mol Biol Rep 2011;38:1225–30.

Sattawat VW, Zhang ZF, Yu GP, et al. GSTM1 and GSTT1 null genotypes and the risk of gastric cancer: a case-control study in a Chinese population. Cancer Epidemiol Biomarkers Prev 2009;18:73–80.

Pacakti S, Polimanti R, Porreca F, et al. GSTT1 and GSTM1 gene polymorphisms in European and African populations. Mol Biol Rep 2011;38:1225–30.

Sattawat VW, Zhang ZF, Yu GP, et al. GSTM1 and GSTT1 null genotypes and the risk of gastric cancer: a case-control study in a Chinese population. Cancer Epidemiol Biomarkers Prev 2009;18:73–80.